凯普生物(300639) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥302,111,598.82, a decrease of 80.00% compared to ¥1,510,718,034.62 in the same period last year[5] - Net profit attributable to shareholders was ¥65,353,876.62, down 86.92% from ¥499,725,567.45 year-on-year[5] - Basic and diluted earnings per share were both ¥0.15, a decline of 86.96% compared to ¥1.15 in the same period last year[5] - The company reported a revenue of 302.11 million RMB for the first quarter, representing a year-over-year decline of 80.00%[20] - The net profit attributable to shareholders was 65.35 million RMB, down 86.92% compared to the previous year[20] - The net profit after deducting non-recurring gains and losses was 59.94 million RMB, reflecting a decrease of 87.81% year-over-year[20] - Total operating revenue for Q1 2023 was CNY 302,111,598.82, a significant decrease from CNY 1,510,718,034.62 in the same period last year, representing a decline of approximately 80%[35] - Net profit for Q1 2023 was CNY 46,306,727.49, a sharp decline compared to CNY 551,717,509.33 in Q1 2022, reflecting a decrease of approximately 92%[37] - Total comprehensive income for the first quarter was CNY 19,249,083.27, a decrease from CNY 549,883,632.07 in the previous period[38] Cash Flow and Assets - The net cash flow from operating activities decreased by 42.00% to ¥69,178,080.03 from ¥119,282,306.10 in the previous year[5] - The company's cash and cash equivalents decreased to CNY 128,308,186.77 from CNY 108,691,019.37, reflecting an increase of approximately 18%[34] - The ending balance of cash and cash equivalents was CNY 932,450,807.46, down from CNY 1,024,775,861.20 at the beginning of the period[41] - Total assets at the end of Q1 2023 were ¥6,441,765,403.41, down 4.30% from ¥6,731,125,843.21 at the end of the previous year[5] - As of the end of the reporting period, the company's accounts receivable balance decreased to RMB 2,437.29 million from RMB 2,721.53 million at the beginning of the year, representing a reduction of approximately 10.5%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 41,458[15] - The largest shareholder, Hong Kong Science and Technology Venture Co., Ltd., holds 29.30% of the shares, totaling 128,798,878 shares[15] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top four shareholders alone holding over 60%[15] - The company repurchased 5,234,000 shares, accounting for 1.19% of total shares, ranking seventh among all shareholders[16] - The company has repurchased a total of 2,584,800 shares, accounting for 0.59% of the total share capital, with a total transaction amount of approximately RMB 53.01 million[26] Investment and Development - The company invested ¥102,356,893.50 in construction projects, a 74.60% increase attributed to the expansion of the Cap Biomedical Science Park[10] - The company invested RMB 40.76 million in R&D during the reporting period, marking a year-on-year increase of 27.11%[21] - The company obtained a total of 73 medical device registration/filing certificates, including 25 Class III, 7 Class II, and 41 Class I certificates[21] - The company has established a national medical testing network with 36 medical laboratories and 16 physical and chemical laboratories[21] - The company successfully acquired land use rights for the construction of the Cape Medical Science Park for RMB 90.79 million[23] - The company is applying for a syndicated loan for the Cape Medical Science Park construction project, with the company providing guarantees for the loan[27] Operational Challenges - The company reported a significant decrease in revenue from nucleic acid testing, which was the primary reason for the decline in overall revenue[11] - The company experienced a significant decline in revenue due to a sharp decrease in demand for nucleic acid testing services[20] - The company has not reported any new product developments or market expansions during this period[20] - The company's stock has seen limited trading activity, with some shareholders engaging in margin trading[16] Financial Ratios and Costs - The company’s weighted average return on equity decreased by 9.22 percentage points to 5.29% from 14.51% in the previous year[5] - Total operating costs for Q1 2023 were CNY 269,430,605.18, down from CNY 796,568,792.36 in the previous year, indicating a reduction of about 66%[35] - Research and development expenses increased to CNY 37,746,736.63 in Q1 2023, up from CNY 29,322,132.15 in the same quarter last year, marking an increase of about 29%[35] - Total liabilities for Q1 2023 were CNY 1,197,234,679.97, down from CNY 1,504,241,734.27 in the previous year, indicating a reduction of about 20%[34] - The company reported a financial expense of CNY -18,081,770.43 in Q1 2023, compared to CNY -2,177,163.37 in the previous year, indicating a significant increase in financial costs[37] Miscellaneous - The company did not conduct an audit for the first quarter report[42] - The report was released by the board of directors on April 25, 2023[43]